Drug Interactions 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin OZEMPIC stimulates insulin release in the presence of elevated blood glucose concentrations
Comparable long-term results: Up to 21% weight loss
Mounjaros dual hormone effect (GLP-1 and GIP) may lead to greater appetite control and weight reduction compared with Ozempics single GLP-1 action
Novo Nordisk, the manufacturer of Ozempic (semaglutide approved for diabetes) and Wegovy (semaglutide approved for obesity and other indications) has set a list price of $675 for each of these effective January 1, 2027
Interestingly, substituting the amino acids with alanine enhanced the peptides inhibitory ability (Table 1)
We can help you evaluate your specific research goals, budget, and logistical constraints to make an informed decision